Derma Fade

Octinoxate, Octisalate, Oxybenzone


Pharmagel International Inc
Human Otc Drug
NDC 67879-301
Derma Fade also known as Octinoxate, Octisalate, Oxybenzone is a human otc drug labeled by 'Pharmagel International Inc'. National Drug Code (NDC) number for Derma Fade is 67879-301. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Derma Fade drug includes Octinoxate - 7.5 g/100g Octisalate - 5 g/100g Oxybenzone - 3 g/100g . The currest status of Derma Fade drug is Active.

Drug Information:

Drug NDC: 67879-301
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Derma Fade
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Octinoxate, Octisalate, Oxybenzone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Pharmagel International Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:OCTINOXATE - 7.5 g/100g
OCTISALATE - 5 g/100g
OXYBENZONE - 3 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 18 Jun, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part352
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:PHARMAGEL INTERNATIONAL INC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:4Y5P7MUD51
4X49Y0596W
95OOS7VE0Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
67879-301-511 JAR in 1 BOX (67879-301-51) / 56 g in 1 JAR (67879-301-11)18 Jun, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose sunscreen

Product Elements:

Derma fade octinoxate, octisalate, oxybenzone carbomer interpolymer type a (allyl sucrose crosslinked) allantoin biotin butylene glycol green tea leaf caprylyl glycol cetostearyl alcohol citric acid monohydrate tangerine peel cyperus rotundus tuber dimethicone edetate disodium ethylhexyl palmitate ethylhexylglycerin glycerin glyceryl monostearate glycolic acid glycyrrhiza glabra hexylene glycol hydroxyethyl cellulose (3000 mpa.s at 1%) kojic acid lactic acid magnesium ascorbyl phosphate morus alba leaf myristyl laurate myristyl myristate niacin panthenol peg-100 stearate phenoxyethanol phyllanthus emblica fruit propylene glycol fd&c red no. 40 sodium citrate stearic acid edetate sodium trolamine undecylenic acid undecylenoyl glycine water fd&c yellow no. 6 octinoxate octinoxate octisalate octisalate oxybenzone oxybenzone

Indications and Usage:

Uses lightens the appearance of age spots & skin discoloration. provides moderate protections against sunburn.

Warnings:

Warnings warnings using this product – for external use only. avoid contact with eyes. if product gets into the eyes, rinse thoroughly with water. do not use on children under 12 years of age unless directed by a doctor. stop use & consult a doctor if rash or irritation develops and persists.

Dosage and Administration:

Directions apply to age spots and skin discoloration. can be used as a full face moisturizing treatment and sunscreen before sun exposure.

Package Label Principal Display Panel:

Dermafade_final_box df_pf_final_rev


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.